Hansoh Pharmaceutical Group Company Limited (3692) AI Stock Analysis

• Market Cap: HK$203.99B
• Dividend Yield: 1%
• Average Volume (3M): 10.06M
• Price to Earnings (P/E): 42.9
• Beta (1Y): 0.84
• Revenue Growth: 19.29%
• EPS Growth: 31.35%
• Country: HK
• Employees: 8,989
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.31
• Shares Outstanding: 5,947,150,000
• 10 Day Avg. Volume: 10,396,250
• 30 Day Avg. Volume: 10,058,832
• PEG Ratio: -16.10
• Price to Book (P/B): 6.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 50.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$30.91
• Price Target Upside: -9.88% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 76 Outperform
• Price Target: HK$38.00 ▲(10.79%Upside)

Hansoh Pharmaceutical Group's strong financial performance and positive technical indicators drive its stock score. However, overvaluation concerns and the absence of recent cash flows temper the overall outlook. Investors should monitor for cash flow improvements and be cautious of potential short-term corrections due to overbought technical conditions.

Positive Factors

Drug Sales Growth

Sales of innovative drugs, excluding collaboration revenue, saw strong growth of +28.2% YoY, totaling RMB7.9bn.

Financial Performance

Hansoh's FY24 performance was in line with expectations, reporting revenue of RMB12.26bn and attributable net income of RMB4.37bn.

Strategic Partnerships

Hansoh further out-licensed one of its oral small molecule GLP-1R agonists to MSD through a blockbuster deal, indicating sustainable profit from overseas out-licensing deals.

Negative Factors

Hansoh Pharmaceutical Group Company Limited Business Overview & Revenue Model

Company Description

Hansoh Pharmaceutical Group Company Limited (3692) is a leading research-based pharmaceutical company headquartered in China. The company is primarily involved in the development, manufacturing, and marketing of a wide range of pharmaceutical products. Its core product offerings include treatments for oncology, central nervous system diseases, anti-infectives, and diabetes. Hansoh Pharmaceutical is dedicated to innovation and improving healthcare outcomes and has established a strong presence in both domestic and international markets.

How the Company Makes Money

Hansoh Pharmaceutical Group Company Limited generates revenue through the sale of its pharmaceutical products across multiple therapeutic areas. The company's revenue streams are primarily derived from its oncology, central nervous system, anti-infectives, and diabetes treatment products. Hansoh also invests in research and development to create innovative drugs, which can lead to lucrative patents and exclusive marketing rights. Additionally, the company forms strategic partnerships and collaborations with other pharmaceutical enterprises to expand its market reach and enhance its product offerings. These partnerships often involve co-development, co-marketing, or licensing agreements that contribute significantly to its earnings.

Hansoh Pharmaceutical Group Company Limited Financial Statement Overview

Summary

Hansoh Pharmaceutical Group shows strong financial performance with notable revenue and profit growth, strong equity position, and efficient operations. However, the recent absence of operating and free cash flows could pose a risk if not addressed.

Income Statement

Hansoh Pharmaceutical Group has demonstrated strong revenue growth, with a notable increase from the previous year. The gross profit margin is robust, indicating efficient production processes. Their EBIT and EBITDA margins are healthy, reflecting strong operational efficiency. Net profit margin has also improved, showcasing the company's ability to convert revenue into profit effectively.

Balance Sheet

The company maintains an excellent equity position with a high equity ratio, indicating financial stability and low leverage risk. The debt-to-equity ratio is very low, suggesting a conservative approach to leveraging. Return on equity has improved, reflecting efficient use of shareholder funds to generate profits.

Cash Flow

While Hansoh Pharmaceutical has shown positive free cash flow growth over the years, the recent year shows zero operating and free cash flow, which could be a concern for cash generation sustainability. Historically, the operating cash flow to net income ratio was strong, indicating efficient cash conversion, but recent data is lacking for a complete assessment.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.26B	10.10B	9.38B	9.94B	8.69B
Gross Profit	11.16B	9.07B	8.51B	9.06B	7.89B
EBITDA	4.25B	4.20B	2.93B	3.08B	2.99B
Net Income	4.37B	3.28B	2.58B	2.71B	2.57B
Balance Sheet
Total Assets	31.66B	33.04B	30.00B	27.16B	20.79B
Cash, Cash Equivalents and Short-Term Investments	23.39B	24.86B	21.63B	18.94B	13.73B
Total Debt	117.89M	4.30B	4.38B	3.83B	92.75M
Total Liabilities	2.98B	7.24B	7.35B	7.13B	2.92B
Stockholders Equity	28.68B	25.79B	22.65B	20.03B	17.88B
Cash Flow
Free Cash Flow	3.64B	2.90B	2.47B	2.12B	962.83M
Operating Cash Flow	3.86B	3.12B	2.74B	2.58B	2.39B
Investing Cash Flow	-1.39B	1.07B	-5.94B	-2.26B	-2.87B
Financing Cash Flow	-6.07B	-753.70M	-818.14M	3.42B	-1.04B

Hansoh Pharmaceutical Group Company Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 34.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3692, the sentiment is Positive. The current price of 34.3 is above the 20-day moving average (MA) of 32.59, above the 50-day MA of 29.25, and above the 200-day MA of 21.89, indicating a bullish trend. The MACD of 1.76 indicates Negative momentum. The RSI at 64.51 is Neutral, neither overbought nor oversold. The STOCH value of 45.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3692.

Hansoh Pharmaceutical Group Company Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0512	78 Outperform	HK$33.54B	13.41	15.61%	2.84%	10.59%	31.83%
3692	76 Outperform	HK$203.99B	42.91	16.09%	1.00%	19.29%	31.35%
1513	74 Outperform	HK$39.36B	15.79	14.56%	0.10%	-5.37%	6.28%
0874	66 Neutral	HK$45.43B	10.23	7.22%	0.27%	-4.07%	-35.32%
2196	65 Neutral	HK$72.22B	16.73	6.22%	0.10%	-2.82%	11.93%
3320	62 Neutral	€35.06B	9.65		4.62%	―	―
Sector *	52 Neutral	$7.63B	0.11	-62.96%	2.08%	16.16%	0.31%

Hansoh Pharmaceutical Group Company Limited Corporate Events

Hansoh Pharmaceutical Successfully Concludes AGM with Key Resolutions Passed

Hansoh Pharmaceutical Group Company Limited held its Annual General Meeting on June 20, 2025, where all proposed resolutions were passed with significant support. Key decisions included the adoption of the company’s financial statements, approval of a final dividend, re-election of directors, and granting of mandates for share repurchase and issuance. These resolutions reflect the company’s stable financial health and strategic plans for growth, potentially enhancing shareholder value and strengthening its market position.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

Hansoh Pharmaceutical’s Aumolertinib Mesilate Tablets Approved for UK Market

Hansoh Pharmaceutical Group Company Limited announced that its innovative drug, Aumolertinib Mesilate Tablets, has been approved by the UK’s Medicines and Healthcare Products Regulatory Agency for marketing. This approval marks a significant milestone for the company as it expands its market presence in the UK, offering treatment options for patients with specific mutations of non-small cell lung cancer. The approval is expected to enhance the company’s position in the pharmaceutical industry and provide new opportunities for growth.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

Hansoh Pharmaceutical Enters Strategic License Agreement with Regeneron

Hansoh Pharmaceutical Group Company Limited has entered into a license agreement with Regeneron Pharmaceuticals, Inc., granting Regeneron an exclusive worldwide license to develop, manufacture, and commercialize the investigational drug HS-20094 outside of the Chinese Mainland, Hong Kong, and Macau. This agreement could potentially bring Hansoh up to $1.93 billion in milestone payments and double-digit royalties, enhancing its market position and leveraging its technology platforms. The agreement is seen as beneficial for Hansoh’s shareholders and aligns with the company’s strategic goals.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

Hansoh Pharmaceutical’s Third Biologics License Application for XINYUE Accepted

Hansoh Pharmaceutical Group Company Limited announced that the National Medical Products Administration has accepted the third biologics license application for XINYUE (Inebilizumab Injection) for treating generalized myasthenia gravis in adult patients. This acceptance marks a significant step in expanding the treatment options for this condition, reinforcing Hansoh’s position in the pharmaceutical industry and potentially enhancing its market share and influence in the region.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

Hansoh Pharma’s HS-20118 Tablets Gain Clinical Trial Approval

Hansoh Pharmaceutical Group Company Limited has announced that its self-developed HS-20118 tablets have received Clinical Trial Approval from China’s National Medical Products Administration. This approval allows the company to proceed with clinical trials for the treatment of moderate to severe plaque psoriasis, potentially enhancing its position in the pharmaceutical industry and offering new treatment options for patients.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

Hansoh Pharmaceutical Gains Approval for Clinical Trials of Innovative Drug

Hansoh Pharmaceutical Group Company Limited has announced that its self-developed innovative drug, HS-10542 capsules, has received Clinical Trial Approval from China’s National Medical Products Administration. This approval allows the company to conduct clinical trials for the treatment of paroxysmal nocturnal hemoglobinuria and immunoglobulin A nephropathy, potentially strengthening its position in the pharmaceutical industry and offering new treatment options for these conditions.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

Hansoh Pharmaceutical Receives Approval for Clinical Trials of HS-10510 Tablets

Hansoh Pharmaceutical Group Company Limited announced that its self-developed innovative drug, HS-10510 tablets, has received Clinical Trial Approval from China’s National Medical Products Administration. This approval allows the company to proceed with clinical trials targeting primary hypercholesterolemia and mixed dyslipidemia, potentially strengthening its position in the pharmaceutical industry and expanding its product offerings.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

Hansoh Pharmaceutical Announces 2025 Annual General Meeting Agenda

Hansoh Pharmaceutical Group Company Limited has announced its upcoming annual general meeting scheduled for June 20, 2025, in Hong Kong. Key agenda items include the adoption of the 2024 financial statements, approval of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, the company seeks shareholder approval for mandates to repurchase shares and issue new shares, reflecting strategic moves to enhance shareholder value and operational flexibility.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

Hansoh Pharmaceutical’s Ameile Gains Fourth Indication Approval for NSCLC Treatment

Hansoh Pharmaceutical Group announced that its innovative drug Ameile (Aumolertinib Mesilate Tablets) has received approval from the National Medical Products Administration of China for a new indication. This approval allows Ameile to be used as an adjuvant treatment for adult patients with stage II to IIIB non-small cell lung cancer (NSCLC) with specific genetic mutations. This marks the fourth indication approval for Ameile, enhancing its market positioning and expanding its treatment options for NSCLC.

Hansoh Pharma’s HS-20089 Gains Breakthrough Therapy Status in China

Hansoh Pharmaceutical Group Company Limited announced that its self-developed B7-H4-targeted antibody-drug conjugate, HS-20089, has been granted Breakthrough-Therapy-Designated status by China’s National Medical Products Administration. This designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The product is in Phase III clinical trials in China and has an exclusive worldwide license agreement with GlaxoSmithKline for development and commercialization outside Greater China, indicating significant potential for global market expansion.

Hansoh Pharmaceutical Grants RSUs to Employees and Executive Director

Hansoh Pharmaceutical Group Company Limited has announced the grant of restricted share units (RSUs) under its Post-IPO RSU Scheme, involving 8,560,990 shares to 776 grantees, including one executive director and 775 employees. This move is part of the company’s strategy to incentivize its workforce, aligning their performance with the company’s goals, and potentially enhancing its market position by retaining key talent.

Hansoh Pharmaceutical Announces Final Dividend for 2024

Hansoh Pharmaceutical Group Company Limited announced a final cash dividend of HKD 0.1353 per share for the financial year ending December 31, 2024. The dividend is subject to shareholders’ approval on June 20, 2025, and will be paid on July 25, 2025. This announcement reflects the company’s stable financial performance and commitment to returning value to its shareholders, potentially strengthening its market position and investor confidence.